Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
According to Vertex Pharmaceuticals, approximately 300 additional ... 6 years and older with at least 1 qualifying non-F508del Trikafta-responsive mutation and with no exclusionary mutation.
Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...
FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options ... If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as ...
Vertex Pharmaceuticals stock declined almost 13 ... driven by higher sales of Trikafta/Kaftrio in younger age groups. In the first nine months of 2024, Vertex’s revenues rose 10%.
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Ratings for Vertex Pharmaceuticals (NASDAQ ... Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally.
Vertex Pharmaceuticals is a global biotechnology ... Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback